**FOI Ref: 6382**

**Category(ies): Clinical - Drugs**

**Subject: Usage of Intra-Vitreal Injections or Implants**

**Date Received: 11/05/2022**

|  |  |
| --- | --- |
| **Your request:** | **Our response:** |
| 1. How many of the following intra-vitreal injections/implants has your trust administered in the four-month period from January to April 2022:  * Aflibercept * Bevacizumab * Brolucizumab * Dexamethasone * Fluocinolone acetonide * Ranibizumab | * Aflibercept – 792 * Bevacizumab – 0 * Brolucizumab  - 0 * Dexamethasone  - 3 * Fluocinolone acetonide – 3 * Ranibizumab – 1040 |
| 1. Please provide the number of injections/implants by eye condition for the four-month period from January to April 2022. | |  |  |  |  | | --- | --- | --- | --- | | Number of Injections/Implants: Jan to Apr 2022 | | | | |  | **Eye Conditions** | | | | **Treatment** | Wet Age-Related Macular Degeneration wAMD | Diabetic Macular Degeneration DMO | Retinal Vein Occulusion RVO | | Aflibercept | 412 | 201 | 179 | | Bevacizumab | 0 | 0 | 0 | | Brolucizumab | 0 | 0 | 0 | | Dexamethasone | 0 | 0 | 3 | | Fluocinolone acetonide | 0 | 2 | 1 | | Ranibizumab | 579 | 232 | 229 | |